Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Xu, Yunze
NCT05401279: Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer	Recruiting	2	20	RoW	Tislelizumab, Gemcitabine, Cisplatin	RenJi Hospital	Urothelial Carcinoma Bladder, PD-1 Inhibitor	04/24	05/25
NCT05243173: Biomarkers of Response to Systemic Treatments in FH-deficient RCC	Recruiting	N/A	100	RoW	Sequencing	RenJi Hospital	Metabolomics, Renal Cell Carcinoma, FH-Deficient RCC, Systemic Treatments	06/24	06/24